Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 2Urogenital Neoplasms 1Neoplasms by Site 1Neoplasms 1Genital Neoplasms, Male 1Genital Diseases, Male 1Breast Neoplasms 1

Interventions

selpercatinib 2pembrolizumab 2abemaciclib 2Pemetrexed 2Nivolumab 2Irinotecan 2Fulvestrant 2Abiraterone Acetate 2ribociclib 1repotrectinib 1relatlimab 1pralsetinib 1pamiparib 1palbociclib 1osimertinib 1onapristone 1olaparib 1glutathione pegylated liposomal doxorubicin 1ficlatuzumab 1exemestane 1enzalutamide 1elacestrant 1cobimetinib 1abiraterone 1Trastuzumab 1Taxes 1Tamoxifen 1STX-478 1Radiation 1RAD1901 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms by Site × BAY 86-7548 × Clear all
NCT02483884 2017-03-22

PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate Cancer

Lantheus Biosciences Ltd.

Phase 1/2 Terminated
30 enrolled
Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡